FLT3 and acute myeloid leukemia: Janssen et al. reported a notable synergy between venetoclax and gilteritinib in FLT3 wild-type high-risk AML, mediated through the suppression of the antiapoptotic protein myeloid cell leukemia-1 (Mcl-1)[96].